CS Genetics, an innovative genomics technology company, today announced a strategic partnership with ROSALIND, the premier SaaS platform empowering life science research across diverse technologies. By combining the wet-bench simplicity of CS Genetics’ SimpleCell™ platform with ROSALIND’s multi-omics analysis, this partnership will help researchers significantly expand their single-cell capabilities.
The integrated solution will unlock insights faster and more efficiently, empowering scientists to drive breakthrough discoveries at a fraction of the traditional cost.
“At CS Genetics, we’ve developed the SimpleCell™ platform to redefine the economics of single-cell genomics, removing the need for expensive instruments and slashing per-sample costs,” said Jay Harger, Chief Operating Officer at CS Genetics. “By partnering with ROSALIND®, we’re enabling biopharma and academic teams to run much larger, more rigorous single-cell projects while accessing best-in-class analysis and collaboration tools.”
Also Read: Sana Biotechnology Appoints Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
The CS Genetics solution introduces a unique instrument-free, solution-phase platform powered by Kinetic Confinement, that delivers unprecedented simplicity and scalability. With its ability to integrate into standard lab workflows at lower costs, both biopharma and academic researchers can now conduct larger single-cell studies, generating critical insights with speed and scale.
“We’re thrilled to partner with CS Genetics because they’ve solved two key barriers to single-cell adoption: complexity and cost,” said Tim Wesselman, ROSALIND® Chief Executive Officer. “SimpleCell™ allows biopharma teams to scale up their single-cell research like never before, while ROSALIND® provides the analytical power to quickly interpret, collaborate on, and leverage those insights. Together, we’re not just speeding up science—we’re maximizing ROI by enabling more projects and empowering larger scientific teams.”
This partnership aims to democratize single-cell genomics, bringing this cutting-edge technology to more biopharma companies and academic labs while enhancing scientific collaboration and discovery.
SOURCE: PRNewswire